GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Moderate Buy" from Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fifteen ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $9.36.

GDRX has been the topic of several recent research reports. UBS Group cut their target price on shares of GoodRx from $9.00 to $8.50 and set a "neutral" rating on the stock in a research report on Friday, August 9th. Citigroup cut their target price on shares of GoodRx from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Friday, August 9th. Raymond James upgraded shares of GoodRx from an "outperform" rating to a "strong-buy" rating and set a $10.00 target price on the stock in a research report on Friday, August 9th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 target price on shares of GoodRx in a research report on Friday, August 16th.

Insider Buying and Selling at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.17% of the stock is currently owned by company insiders.

Institutional Trading of GoodRx

Hedge funds and other institutional investors have recently bought and sold shares of the business. American Century Companies Inc. bought a new stake in shares of GoodRx in the 2nd quarter worth $18,183,000. Rubric Capital Management LP grew its stake in shares of GoodRx by 76.5% in the 2nd quarter. Rubric Capital Management LP now owns 3,736,802 shares of the company's stock worth $29,147,000 after acquiring an additional 1,619,748 shares in the last quarter. Millennium Management LLC grew its stake in shares of GoodRx by 36.5% in the 2nd quarter. Millennium Management LLC now owns 4,121,939 shares of the company's stock worth $32,151,000 after acquiring an additional 1,102,758 shares in the last quarter. Picton Mahoney Asset Management bought a new stake in shares of GoodRx in the 1st quarter worth $3,467,000. Finally, Raymond James & Associates grew its stake in shares of GoodRx by 212.6% in the 3rd quarter. Raymond James & Associates now owns 394,006 shares of the company's stock worth $2,734,000 after acquiring an additional 267,951 shares in the last quarter. Institutional investors own 63.77% of the company's stock.

GoodRx Price Performance

Shares of GoodRx stock traded up $0.07 during midday trading on Friday, hitting $6.19. 951,440 shares of the company traded hands, compared to its average volume of 1,369,045. The stock has a market cap of $2.35 billion, a price-to-earnings ratio of -47.62, a PEG ratio of 4.03 and a beta of 1.37. The company has a debt-to-equity ratio of 0.96, a quick ratio of 7.32 and a current ratio of 7.32. The firm's fifty day moving average price is $7.15 and its 200-day moving average price is $7.55. GoodRx has a 12 month low of $4.14 and a 12 month high of $9.26.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $200.60 million for the quarter, compared to the consensus estimate of $200.47 million. GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. The company's revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period last year, the firm posted $0.02 earnings per share. As a group, sell-side analysts forecast that GoodRx will post 0.14 earnings per share for the current year.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.